Babcock University Research Portal

Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice

Authors: KALE Oluwafemi , Olufunsho , Ogundare Temitope , Ekor Martins

Publication Type: Journal article

Journal: Fundamental & Clinical Pharmacology

ISSN Number:

Downloads

Views

Abstract

This study investigated the modulatory and chemopreventive benefit of amlodipine
(AML), a dihydropyridine calcium channel antagonist, against neurobehavioural
abnormalities (NAs) associated with chlorpromazine (CPZ) toxicity in mice. Adult
mice were divided into five groups of six animals/group. Group 1 (control) was
administered saline (10 mL/kg i.p.). Group 2 received CPZ (2 mg/kg i.p.). Groups
3 and 4 received bromocriptine (BMC, 2.5 mg/kg s.c.) and AML (1 mg/kg s.c.),
respectively, while group 5 received their combination. Groups 3–5 later received
CPZ 30 min after initial treatments. Animals were subjected to neurobehavioural
tests and euthanized 18 h later. CPZ-induced NAs were characterized by significant
increase (P < 0> activity reaction time in mice. There were also significant (P < 0> malondialdehyde levels and decreased locomotion plus learning and memory
parameters (P < 0> motor deficits in the mice. While pretreatment with BMC alone attenuated
CPZ-associated catalepsy, its combination with AML further protected mice against
NAs. Furthermore, BMC pretreatment did not affect CPZ-induced increase in
malondialdehyde level, but AML or BMC+AML significantly (P < 0> malondialdehyde in the CPZ-treated rats. Reduced glutathione levels and activities
of superoxide dismutase and catalase remained elevated in all treatment groups. In
conclusion, data from this study suggest possible chemopreventive benefit of AML
alone or in combination with BMC against CPZ-associated neurobehavioural deficits.
The ameliorative effect of AML may be related to its antioxidant and/or calcium
channel blocking property.

Access to Documents

External Link
Download
Digital Object Identifier

Keywords

KALE,O. Olufunsho,A. Ogundare ,T. Ekor,M. . (2017). Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice, 31 (), 329-329.

KALE,O. Olufunsho,A. Ogundare ,T. Ekor,M. . "Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice" 31, no (), (2017): 329-329.

KALE,O. and Olufunsho,A. and Ogundare ,T. and Ekor,M. and . (2017). Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice, 31 (), pp329-329.

KALEO, OlufunshoA, Ogundare T, EkorM, . Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice. 2017, 31 ():329-329.

KALE,Oluwafemi , Olufunsho,Awodele , Ogundare ,Temitope , and Ekor,Martins . "Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice", 31 . (2017) : 329-329.

K.Oluwafemi O.Awodele O.Temitope & E.Martins , "Amlodipine, an L-type calcium channel blocker, protects against chlorpromazineinduced neurobehavioural deficits in mice" vol.31, no., pp. 329-329, 2017.

Access to Documents

Keywords

About Us

Admissions

Contact Us

Policies

ALUMNI

STUDENT POPULATION